Unknown PHASE4 INTERVENTIONAL 2-arm NCT00707070

Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis (CobAcE)

Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis

Sponsor: Universita di Verona

Conditions Chronic Plaque Psoriasis

Interventions efalizumab plus acitretin efalizumab plus placebo

Updated 5 times since 2017 Last updated: Jun 27, 2008 Started: Sep 30, 2008 Primary completion: Oct 31, 2009 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Chronic Plaque Psoriasis and is currently ongoing. Universita di Verona leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universita di Verona

Data source: Universita di Verona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Verona, Italy